StockData

Arvinas vs Foghorn Therapeutics

ARVN and FHTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARVN and FHTX compare

Arvinas is the larger company, worth 4.1 times as much as Foghorn Therapeutics ($446M against $109M).

Foghorn Therapeutics grew revenue faster over the last twelve months (52.0% versus −15.0% for Arvinas).

Arvinas keeps more of each dollar of sales as profit, with a net margin of 2.9% compared with −176% at Foghorn Therapeutics.

Foghorn Therapeutics scores higher on the StockData Score (9 against 8 for Arvinas), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARVNFHTX
Size and price
Market cap$446M$109M
Share price$6.82$1.83
Change, 1 year−35.5%−61.0%
Change, 5 years−91.3%−86.6%
Beta (5Y)2.002.82
Employees246106
StockData Score
Total score89 (better)
Valuation score11
Growth score12 (better)
Performance score3 (better)1
Health score35 (better)
Dividend score00
Valuation
P/E42.6×–
P/S1.4× (better)3.0×
P/B0.8×–
FCF yield−46.8% (better)−77.6%
Growth
Revenue growth (TTM)−15.0%52.0% (better)
Revenue growth, 5Y average58.9%135% (better)
Profitability
Operating margin−5.7% (better)−198%
Net margin2.9% (better)−176%
FCF margin−65.9% (better)−229%
Return on equity1.6%–
Financial health
Debt / equity0.00–
Current ratio7.91 (better)3.36
Altman Z-score0.65 (better)−4.61
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions86.0%75.6%
Held by insiders7.8%36.3%
Insider net buying, 12 months−$1.2M–
Short interest, % of float9.5%6.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.